复发或难治性慢性淋巴细胞白血病CD19 CAR-T细胞治疗长期结局的相关因素
分析47例复发或难治性慢性淋巴细胞白血病和(或)Richter转化患者接受CD19 CAR-T细胞治疗1/2期临床试验的长期结局,中位随访79.6个月。中位无进展生存期8.9个月,6年无进展生存率17.8%;淋巴细胞清除前最大标准化摄取值升高和巨块型病变(≥5 cm)与较短无进展生存期相关,而第+28天完全缓解、可测量残留病阴性及CAR-T细胞扩增峰值较高和持久性较长与较长无进展生存期相关。
要点
- 中位无进展生存期8.9个月,6年无进展生存率17.8%。
- 淋巴细胞清除前最大标准化摄取值升高和巨块型病变(≥5 cm)与较短无进展生存期相关。
- 第+28天完全缓解、可测量残留病阴性和CAR-T细胞扩增峰值较高及持久性较长与较长无进展生存期相关。
核心结论
- CD19 CAR-T细胞治疗在一部分复发或难治性慢性淋巴细胞白血病患者中实现了持久缓解并具有治愈潜力。
研究设计与样本
- 分析47例复发或难治性慢性淋巴细胞白血病和(或)Richter转化患者,接受CD19 CAR-T细胞治疗1/2期临床试验,中位随访79.6个月。
主要发现
- 中位无进展生存期为8.9个月,6年无进展生存率为17.8%。
- 6年缓解持续率和总生存率分别为26.4%和31.2%。
- 淋巴细胞清除前最大标准化摄取值升高与较短无进展生存期相关(HR 1.15;95%CI 1.07-1.23;P < .001)。
- 淋巴细胞清除前巨块型病变(≥5 cm)与较短无进展生存期相关(HR 2.12;95%CI 1.06-4.26;P = .034)。
- 第+28天正电子发射断层扫描-计算机断层扫描完全缓解与较长无进展生存期相关(HR 0.13;95%CI 0.04-0.40;P < .001)。
关键数值与推荐
- 第+28天多参数流式细胞术可测量残留病阴性与较长无进展生存期相关(HR 0.08;95%CI 0.03-0.22;P < .001)。
- 第+28天二代测序可测量残留病阴性与较长无进展生存期相关(HR 0.21;95%CI 0.08-0.51;P < .001)。
- CD8+ CAR-T细胞扩增峰值较高与较长无进展生存期相关(HR 0.49;95%CI 0.36-0.68;P < .001)。
- CD4+ CAR-T细胞扩增峰值较高与较长无进展生存期相关(HR 0.47;95%CI 0.33-0.69;P < .001)。
- CAR-T细胞持久性较长与较长无进展生存期相关(HR 0.56;95%CI 0.44-0.72;P < .001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High response rates have been reported after CD19-targeted chimeric antigen receptor-modified (CD19 CAR) T-cell therapy for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), yet the factors associated with duration of response in this setting are poorly characterized. We analyzed long-term outcomes in 47 patients with R/R CLL and/or Richter transformation treated on our phase 1/2 clinical trial of CD19 CAR T-cell therapy with an updated median follow-up of 79.6 months. Median progression-free survival (PFS) was 8.9 months, and the 6-year PFS was 17.8%. Maximum standardized uptake value (hazard ratio [HR], 1.15; 95% confidence interval [CI], 1.07-1.23; P < .001) and bulky disease (≥5 cm; HR, 2.12; 95% CI, 1.06-4.26; P = .034) before lymphodepletion were associated with shorter PFS. Day +28 complete response by positron emission tomography-computed tomography (HR, 0.13; 95% CI, 0.04-0.40; P < .001), day +28 measurable residual disease (MRD) negativity by multiparameter flow cytometry (HR, 0.08; 95% CI, 0.03-0.22; P < .001), day +28 MRD negativity by next-generation sequencing (HR, 0.21; 95% CI, 0.08-0.51; P < .001), higher peak CD8+ CAR T-cell expansion (HR, 0.49; 95% CI; 0.36-0.68; P < .001), higher peak CD4+ CAR T-cell expansion (HR, 0.47; 95% CI; 0.33-0.69; P < .001), and longer CAR T-cell persistence (HR, 0.56; 95% CI, 0.44-0.72; P < .001) were associated with longer PFS. The 6-year duration of response and overall survival were 26.4% and 31.2%, respectively. CD19 CAR T-cell therapy achieved durable responses with curative potential in a subset of patients with R/R CLL. This trial was registered at www.clinicaltrials.gov as #NCT01865617.
引用
- Liang EC, Albittar A, Huang JJ, et al. Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL. Blood Adv. 2023. PMID: 37774014. doi:10.1182/bloodadvances.2023011399
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。